Porphyria: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Related to defect(s) in heme synthesis causing a buildup of porphyrins | |||
*Autosomal dominant, but poor penetrance | |||
* Inherited and/or acquired disorders of in which there are enzyme deficiencies involved in heme biosynthesis. | * Inherited and/or acquired disorders of in which there are enzyme deficiencies involved in heme biosynthesis. | ||
* Heme is a component of many essential hemoproteins, such as hemoglobin, myoglobin and cytochromes, including the cytochrome P450 enzymes | * Heme is a component of many essential hemoproteins, such as hemoglobin, myoglobin and cytochromes, including the cytochrome P450 enzymes | ||
| Line 5: | Line 7: | ||
* The enzyme deficiencies in porphyria limit the capacity of the liver to increase heme synthesis. | * The enzyme deficiencies in porphyria limit the capacity of the liver to increase heme synthesis. | ||
* When drugs, hormones or other factors that induce ALAS and CYPs are given, ALA and porphobilinogen (PBG) are overproduced and accumulate, and a neurovisceral attack may develop | * When drugs, hormones or other factors that induce ALAS and CYPs are given, ALA and porphobilinogen (PBG) are overproduced and accumulate, and a neurovisceral attack may develop | ||
===Triggers=== | |||
*Infection, metabolic stress | |||
*Carbohydrate deficiency | |||
*Tobacco, EtOH | |||
*Porphyrinogenic drugs: sulfonamides, barbiturates, rifampin or metoclopramide | |||
==Clinical Features== | ==Clinical Features== | ||
*Gastrointestinal symptoms | *Gastrointestinal symptoms | ||
**Acute [[abdominal pain]] (85-90% of attacks) | **Acute [[abdominal pain]] (85-90% of attacks) | ||
| Line 28: | Line 35: | ||
==Diagnosis== | ==Diagnosis== | ||
''Consider porphyria in patients with abdominal pain that is unexplained after an initial workup has excluded common causes (appendicitis, cholecystitis, pancreatitis, etc).'' | ''Consider porphyria in patients with abdominal pain that is unexplained after an initial workup has excluded common causes (appendicitis, cholecystitis, pancreatitis, etc).'' | ||
* Spot urinary porphobilinogen (sendout at most hospitals) | |||
* | |||
**Normal = 0-4 mg/day | **Normal = 0-4 mg/day | ||
**acute attack, spot urine can be 20-200 mg/L | **acute attack, spot urine can be 20-200 mg/L | ||
| Line 35: | Line 41: | ||
==Management== | ==Management== | ||
*Analgesia | |||
*Avoid offending meds | |||
**Most seizure meds contraindicated: [[Benzodiazepines]], [[gabapentin]], [[levetiracetam]], and [[vigabatrin]] okay | |||
**Avoid [[reglan]] | |||
*Glucose load | |||
**Decreases porphyrin production | |||
**Typical protocol is D10W 3-4 liters daily x 4 days | |||
**Risk of hyponatremia given significant free water load | |||
*Hemin | |||
**Decreases porphyrin production, significantly more potent than glucose | |||
**Recommended for most cases requiring hospitalization, or any with neurologic symptoms | |||
**3-4 mg/kg daily for 4 days | |||
**Can cause significant infusion site phlebitis - minimize by reconstituting in 25% albumin; consider central venous administration | |||
**Very expensive - around $8000 per 313 mg vial | |||
*Hemin (Panhematin®) 3-4 mg/kg IV daily x 4 days | *Hemin (Panhematin®) 3-4 mg/kg IV daily x 4 days | ||
**If the diagnosis is confirmed, the first dose can be given in the ED | **If the diagnosis is confirmed, the first dose can be given in the ED | ||
| Line 54: | Line 75: | ||
==External Links== | ==External Links== | ||
http://www.porphyriafoundation.com/ | |||
==References== | ==References== | ||
| Line 59: | Line 81: | ||
# Anderson KE, Bloomer, JR Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR and Desnick RJ. Recommendations for the Diagnosis and Treatment of the Acute Porphyrias. Ann Intern Med 2005; 142:439-450 | # Anderson KE, Bloomer, JR Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR and Desnick RJ. Recommendations for the Diagnosis and Treatment of the Acute Porphyrias. Ann Intern Med 2005; 142:439-450 | ||
# Deacon AC, Peters TJ, Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem. 1998;35:726-32 | # Deacon AC, Peters TJ, Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem. 1998;35:726-32 | ||
<references/> | <references/> | ||
[[Category:Heme/Onc]] | [[Category:Heme/Onc]] | ||
Revision as of 12:24, 11 May 2016
Background
- Related to defect(s) in heme synthesis causing a buildup of porphyrins
- Autosomal dominant, but poor penetrance
- Inherited and/or acquired disorders of in which there are enzyme deficiencies involved in heme biosynthesis.
- Heme is a component of many essential hemoproteins, such as hemoglobin, myoglobin and cytochromes, including the cytochrome P450 enzymes
- The first enzyme in the heme production pathway is ALA synthase (ALAS), which controls the rate of heme synthesis in the liver. This enzyme is down-regulated by heme.
- The enzyme deficiencies in porphyria limit the capacity of the liver to increase heme synthesis.
- When drugs, hormones or other factors that induce ALAS and CYPs are given, ALA and porphobilinogen (PBG) are overproduced and accumulate, and a neurovisceral attack may develop
Triggers
- Infection, metabolic stress
- Carbohydrate deficiency
- Tobacco, EtOH
- Porphyrinogenic drugs: sulfonamides, barbiturates, rifampin or metoclopramide
Clinical Features
- Gastrointestinal symptoms
- Acute abdominal pain (85-90% of attacks)
- Nausea/vomiting
- Constipation and/or diarrhea
- Acute abdominal pain (85-90% of attacks)
- Neurologic symptoms
- Diffuse musculoskeletal pain
- headache
- Sensory loss (40%)
- An indication of a severe and potentially life-threatening attack
- Neuropathy can progress to respiratory failure in hours or days
- Bladder paresis
- Agitation, confusion, combativeness, seizure
Differential Diagnosis
Diffuse Abdominal pain
- Abdominal aortic aneurysm
- Acute gastroenteritis
- Aortoenteric fisulta
- Appendicitis (early)
- Bowel obstruction
- Bowel perforation
- Diabetic ketoacidosis
- Gastroparesis
- Hernia
- Hypercalcemia
- Inflammatory bowel disease
- Mesenteric ischemia
- Pancreatitis
- Peritonitis
- Sickle cell crisis
- Spontaneous bacterial peritonitis
- Volvulus
Extra-abdominal Sources of Abdominal pain
- MI
- Aortic Dissection
- PNA
- PE
- Testicular Torsion
- Herpes Zoster
- Muscle spasm
- Spinal pathology
- Strep Pharyngitis (peds)
- Mononucleosis
- DKA
- ETOH Ketoacidosis
- Uremia
- Sickle Cell Crisis
- SLE
- Vasculitis
- Glaucoma
- Hyperthyroidism
- Methanol Poisoning
- Heavy Metal toxicity
- Addison's disease
- Porphyria
- Paroxysmal nocturnal hemoglobinuria
- Black widow spider bite
Diagnosis
Consider porphyria in patients with abdominal pain that is unexplained after an initial workup has excluded common causes (appendicitis, cholecystitis, pancreatitis, etc).
- Spot urinary porphobilinogen (sendout at most hospitals)
- Normal = 0-4 mg/day
- acute attack, spot urine can be 20-200 mg/L
- Recurrent attacks in a patient with proven acute porphyria are usually similar and can be diagnosed on clinical grounds without biochemical reconfirmation.
Management
- Analgesia
- Avoid offending meds
- Most seizure meds contraindicated: Benzodiazepines, gabapentin, levetiracetam, and vigabatrin okay
- Avoid reglan
- Glucose load
- Decreases porphyrin production
- Typical protocol is D10W 3-4 liters daily x 4 days
- Risk of hyponatremia given significant free water load
- Hemin
- Decreases porphyrin production, significantly more potent than glucose
- Recommended for most cases requiring hospitalization, or any with neurologic symptoms
- 3-4 mg/kg daily for 4 days
- Can cause significant infusion site phlebitis - minimize by reconstituting in 25% albumin; consider central venous administration
- Very expensive - around $8000 per 313 mg vial
- Hemin (Panhematin®) 3-4 mg/kg IV daily x 4 days
- If the diagnosis is confirmed, the first dose can be given in the ED
- Glucose loading
- Has a similar effect, but is much less potent and effective and should be used only for mild attacks.
- Discontinue any inciting drugs
- Treat any electrolyte abnormalities
- Treat pain with narcotic analgesia and nausea with phenothiazines
- beta blockers can be used to treat tachycardia
- Seizures should be treated with gabapentin, benzodiazepines and vigabatrin.
- Patients who have a seizure during an acute porphyria attack rarely need long term anticonvulsant therapy.
Disposition
- Admission to a monitored bed
See Also
External Links
http://www.porphyriafoundation.com/
References
- NR Pimstone, KE. Anderson, B Freilich. (n.d.). Emergency Room Guidelines for Acute Porphyria. American Porphyria Foundation. Retrieved January 11, 2016. From http://www.porphyriafoundation.com/for-healthcare-professionals/emergency-guidelines-for-acute-porphyria#Treatment.
- Anderson KE, Bloomer, JR Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR and Desnick RJ. Recommendations for the Diagnosis and Treatment of the Acute Porphyrias. Ann Intern Med 2005; 142:439-450
- Deacon AC, Peters TJ, Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem. 1998;35:726-32
